	Application No.	Applicant(s)	
Notice of Allowability	09/125,747	25,747 TOROSSIAN, FERNAND NARBEY	
	Examiner	Art Unit	
	Khatol S Shahnan-Shah	1645	
The MAILING DATE of this communication appears All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT Right of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in the or other appropriate communic IGHTS. This application is sub-	is application. If not inclu ation will be mailed in du	uded ue course. <b>THIS</b>
1. This communication is responsive to <u>applicant's amendment</u>	nts and response of 2/9/04.		
2. The allowed claim(s) is/are 17-20 and 23-28, renumbered	claims 1-10 respectively.		
3. The drawings filed on are accepted by the Examine	r.		
<ul> <li>4.  Acknowledgment is made of a claim for foreign priority unally all bloometally al</li></ul>	e been received. e been received in Application N	No	cation from the
* Certified copies not received:			
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		reply complying with the	requirements
5. A SUBSTITUTE OATH OR DECLARATION must be subminformal PATENT APPLICATION (PTO-152) which give			NOTICE OF
<ol> <li>CORRECTED DRAWINGS (as "replacement sheets") must (a) including changes required by the Notice of Draftspers 1) hereto or 2) to Paper No./Mail Date</li> <li>(b) including changes required by the attached Examiner's Paper No./Mail Date</li> <li>Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in the statement sheet (s) and sheet (s) each sheet.</li> </ol>	son's Patent Drawing Review ( . s Amendment / Comment or in .84(c)) should be written on the	the Office action of	the back) of
7. DEPOSIT OF and/or INFORMATION about the depo attached Examiner's comment regarding REQUIREMENT	sit of BIOLOGICAL MATER	IAL must be submitted	. Note the
Attachment(s)  1. ☐ Notice of References Cited (PTO-892)  2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)  3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date  4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ⊠ Interview Sum Paper No./Ma 98), 7. ⊠ Examiner's Am	il Date <u>6/17/04</u> .	,

Application/Control Number: 09/125,747 Page 2

Art Unit: 1645

# Attachment to Notice of Allowance

1. Applicants' amendment and response, received 09 February 2004 are acknowledged. The amendment has been entered. Claims 17-28 have been amended. New claim 29 has been added. Specification pages 1, 3, 4, 6, 7, 8, 9, 10, 14, 15, 16, 18 and 19 have been amended.

2. Claims 17-29 are pending.

## Rejections Withdrawn

3. Rejection of claims 17-28 under 35 U.S.C. 112, first paragraph made in paragraph 9 of the office action mailed 12/12/2003 is withdrawn in view of applicant's amendments.

## **Examiner's Amendment**

4. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee. Authorization for this examiner's amendment was given in a telephone interview with John A. Artz (reg # 25,824) on 6/17/2004.

The application has been amended as follows:

Cancel claims 21, 22 and 29.

Insert the following paragraph in page 1 of the specification on the line below the title: This application is a 371 of PCT/FR97/00334 filed 02/25/1997 which claims priority to the French application number 96 02445 filed 02/26/1996.

#### Allowable Subject Matter

5. Claims 17-20 and 23-28 are allowed. Claims are renumbered 1-10 respectively.

The following is an examiner's statement of reasons for allowance:

Claims are drawn to an immunomodulatory complex comprising:

a) ribosomal nucleic acid extracted from bacteria selected from group consisting of:

Helicobacter pylori, Helicobacter hepaticus, Helicobacter, coronari or a mixture thereof;

b) the amino acids of type III collagen; and

c) bacterial membrane fractions containing glycopeptides and/or lipopolysaccharides.

The prior art fails to teach such composition.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

#### Conclusion

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Khatol S Shahnan-Shah whose telephone number is (571)-272-0863. The examiner can normally be reached on 7:30am-4 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette F Smith can be reached on (571)-272-0864. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only.

Art Unit: 1645

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Khatol Shahnan-Shah, BS, Pharm, MS

Biotechnology Patent Examiner

Art Unit 1645 June 18, 2004

RODNEY P SWARTZ, PH.D